Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.
See the original post:
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Recommendation and review posted by Fredricko
